Is TG Therapeutics Stock Poised for a Rally?

Investor attention is turning to TG Therapeutics as the biopharmaceutical company demonstrates compelling signals that could indicate future strength. Recent institutional investment activity and unanimous analyst confidence suggest growing professional interest despite recent price fluctuations in the shares.

Unanimous Analyst Confidence

Market researchers have expressed consistent optimism regarding TG Therapeutics’ prospects. Six independent analysts currently maintain a unified “Moderate Buy” recommendation for the company. Their collective assessment points toward significant upside potential, with the average price target established at $49.00. This represents an impressive 39% increase from current trading levels.

Key analyst positions include:
* HC Wainwright & Co.: Maintains a “Buy” rating with a $60.00 price target (October 6)
* B. Riley Securities: Reiterated “Buy” with an increased price target of $55.00 (September 17)
* Weiss Ratings: Currently rates the company as “Hold” (October 8)

Institutional Investor Movement

Adding to the positive sentiment, Envestnet Portfolio Solutions Inc. established a new position in TG Therapeutics during the second quarter of 2025. The investment firm purchased shares valued at approximately $543,000, signaling institutional confidence in the company’s long-term trajectory despite recent market performance.

The stock has experienced some pressure over the past ten trading sessions, declining by 3.51%. Over a 30-day period, volatility has measured 4.86%. On Tuesday, shares closed at $35.22, recording a modest gain of 0.28%.

Should investors sell immediately? Or is it worth buying TG Therapeutics?

Fundamental Growth Drivers

The company’s flagship multiple sclerosis treatment, BRIUMVI®, continues to serve as the primary growth engine. Following stronger-than-expected quarterly performance, management has raised its full-year 2025 revenue guidance to between $570 million and $575 million.

Perhaps more significantly, TG Therapeutics is advancing development of a subcutaneous formulation. Since September 8, patient recruitment has been underway for the crucial Phase 3 clinical trial. This innovative delivery method could potentially capture 35-40% of the anti-CD20 market segment that prefers self-administered treatments.

Upcoming Catalyst

Market participants are now looking ahead to the next quarterly earnings report scheduled for November 3. Financial experts project earnings of $0.24 per share. The upcoming results will be closely watched for confirmation of the company’s ambitious growth narrative.

The convergence of institutional backing, analyst endorsement, and fundamental business strength positions TG Therapeutics as a noteworthy investment opportunity, even considering near-term price volatility.